Concordia Healthcare leadership changes get thumbs up at Laurentian

A board and management shakeup at Concordia Healthcare (Concordia Healthcare Stock Quote, Chart, News: TSX:CXR) is a positive, says Laurentian Bank Securities analyst Joseph Walewicz.

On Monday, Concordia announced several personnel changes. Out are board members Ronald Schmeichel and John Huss, who will not stand for re-election, in are industry veterans Edward Borkowski and Rochelle Fuhrmann. Meanwhile, Adrian de Saldanha has been appointed as CFO, succeeding Leith Tessy, and Wayne Kreppner will be promoted to the role of president, replacing Mark Thompson.

“On behalf of the nominating and corporate governance committee and the board of directors as a whole, I am very pleased to announce the nomination of Edward and Rochelle to the board of directors. This nomination is an important part of several recent and ongoing pharmaceutical industry leadership and corporate governance enhancement initiatives that have been undertaken by the board,” said Thompson.

Walewicz says the changes are in keeping with a company that is growing in stature.

“We view the proposed moves as a “maturing” process,” he said. “After nearly 18 months as a public company and much success, Concordia is putting in place a Board with stronger U.S. public company (and specialty pharma) financial expertise, and working to put the FTC investigation behind it. The company has long discussed that a U.S. listing is coming, and we view these changes as part of that process.”

In a research update to clients yesterday, Walewicz maintained his “Buy” rating and one year target price of $106.00 on Concordia Healthcare.

More Cantech Life Sciences

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cxr
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

2 days ago

Is SNAP a buy right now?

He feels the company made forward progress in its recent quarterly results, but Roth MKM analyst Rohit Kulkarni wants to… [Read More]

2 days ago

Bombardier wins price target raise at Desjardins

Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]

3 days ago

Rogers is an undervalued stock, RBC says

With the integration of Shaw Communications underway, RBC analyst Drew McReynolds says Rogers Communications (Rogers Communications Stock Quote, Chart, News,… [Read More]

4 days ago

Tornado Global Hydrovacs is still a double, Beacon says

Following fourth quarter results he describes as "stronger than expected", Beacon Securities analyst Russell Stanley has raised his price target… [Read More]

4 days ago

Sell your Molson Coors stock, Citi says

Ahead if its first quarter results, Citi analyst Filippo Falorni says there is not much to like about Molson Coors… [Read More]

5 days ago